The European Commission has approved Pharming Group’s Joenja® (leniolisib) as the first authorized therapy for activated PI3Kδ syndrome (APDS) in Europe, supported by pivotal Phase II/III data and long-term extension results demonstrating durable efficacy and safety.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
The European Commission approved Pharming Group’s Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and children aged 12 years and older, making it the first authorized therapy for the rare immunodeficiency disorder in Europe. The approval covers all European Union member states, along with Norway, Iceland, and Liechtenstein.
Clinical Evidence
The European authorization was supported by a multinational, triple-blind, placebo-controlled Phase II/III trial (NCT02435173) involving 31 patients aged 12 years and older. The study met its primary endpoints, showing statistically significant reductions in lymph node size and normalization of naïve B-cell counts. Investigators also reported improvements in immunoglobulin levels and broader markers of immune dysregulation.
Regulators additionally reviewed long-term open-label extension data from 37 patients treated with leniolisib for a median of three years. The extension study supported durable clinical benefit and a favorable long-term safety profile. Reported adverse events were generally mild to moderate and included headache, diarrhea, and upper respiratory tract infections.
These findings underscore leniolisib’s targeted mechanism, which directly addresses the underlying immune dysregulation in APDS
Targeted Mechanism
Leniolisib is a selective oral PI3Kδ inhibitor that directly targets the underlying disease mechanism. By suppressing abnormal PI3Kδ signaling, the therapy helps restore immune regulation and reduce immune dysfunction associated with APDS.
Disease Background
APDS is a rare primary immunodeficiency caused by mutations in the PIK3CD or PIK3R1 genes, leading to hyperactivation of the PI3Kδ signaling pathway. The disorder impairs immune cell maturation and function, resulting in recurrent infections, lymphoproliferation, autoimmunity, and gastrointestinal complications. Patients often face delayed diagnosis, with studies reporting a median diagnostic delay of seven years.
Expert Commentary
Leverne Marsh, Pharming’s Chief Commercial Officer, said the approval introduces the first disease-targeted treatment option for European patients with APDS and could significantly improve management of the progressive immune disorder.
Prof. Ulrich Baumann of Hannover Medical School, a clinical investigator in the pivotal trial, highlighted leniolisib’s targeted mechanism and its clinically meaningful impact on immune dysregulation in patients with previously limited therapeutic options.
Launch Strategy
Pharming plans to introduce the oral therapy in Germany during the third quarter of 2026, followed by broader European rollouts after country-level reimbursement negotiations. The company said the approval addresses a major unmet need in a patient population with historically limited treatment options.
Global Expansion
Joenja is already approved in the United States, United Kingdom, Australia, Israel, and Japan. Pharming is pursuing regulatory submissions in Canada and other regions while expanding clinical development into additional primary immunodeficiency disorders linked to immune dysregulation.
Reference
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.